StocksFundsScreenerSectorsWatchlists
CERE

CERE - Cerevel Therapeutics Holdings, Inc. Stock Price, Fair Value and News

42.11USD-0.02 (-0.05%)Market Closed

Market Summary

CERE
USD42.11-0.02
Market Closed
-0.05%

CERE Alerts

  • 1 major insider sales recently.

CERE Stock Price

View Fullscreen

CERE RSI Chart

CERE Valuation

Market Cap

7.6B

Price/Earnings (Trailing)

-17.67

Price/Sales (Trailing)

33.1K

EV/EBITDA

-18.19

Price/Free Cashflow

-22.09

CERE Price/Sales (Trailing)

CERE Profitability

EBT Margin

-193008.48%

Return on Equity

-64.24%

Return on Assets

-34.81%

Free Cashflow Yield

-4.53%

CERE Fundamentals

CERE Revenue

Revenue (TTM)

224.0K

CERE Earnings

Earnings (TTM)

-432.8M

Earnings Growth (Yr)

-42.94%

Earnings Growth (Qtr)

-37.67%

Breaking Down CERE Revenue

Last 7 days

-0.5%

Last 30 days

1.6%

Last 90 days

-1.2%

Trailing 12 Months

67.8%

How does CERE drawdown profile look like?

CERE Financial Health

Current Ratio

10.92

Debt/Equity

0.5

Debt/Cashflow

-1.01

CERE Investor Care

Shares Dilution (1Y)

15.91%

Diluted EPS (TTM)

-2.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20220000
20210000
20201.3M1.0M489.6K224.0K
20190001.6M

Tracking the Latest Insider Buys and Sells of Cerevel Therapeutics Holdings, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
coles n anthony
sold
-2,116,640
42.3328
-50,000
-
Apr 01, 2024
coles n anthony
acquired
175,000
3.5
50,000
-
Mar 04, 2024
coles n anthony
acquired
175,000
3.5
50,000
-
Mar 04, 2024
coles n anthony
sold
-2,050,550
41.011
-50,000
-
Feb 29, 2024
coles n anthony
acquired
175,000
3.5
50,000
-
Feb 29, 2024
coles n anthony
sold
-2,057,890
41.1578
-50,000
-
Feb 20, 2024
perceptive advisors llc
gifted
-
-
-170,317
-
Feb 07, 2024
renger john
sold
-89,776
41.5441
-2,161
chief scientific officer
Feb 07, 2024
coles n anthony
sold
-104,110
41.5441
-2,506
-
Feb 06, 2024
renger john
acquired
-
-
5,020
chief scientific officer

1–10 of 50

Which funds bought or sold CERE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 05, 2024
GAMMA Investing LLC
new
-
169
169
-%
Apr 05, 2024
CWM, LLC
added
0.99
-
9,000
-%
Mar 29, 2024
Kapitalo Investimentos Ltda
new
-
7,632,000
7,632,000
1.57%
Mar 27, 2024
NOMURA HOLDINGS INC
new
-
954,000
954,000
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-31.62
68,083
275,600
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
new
-
13,992,000
13,992,000
0.05%
Mar 11, 2024
VANGUARD GROUP INC
added
15.75
173,612,000
312,699,000
0.01%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
228
38,094,000
45,177,800
-%
Feb 29, 2024
Scarborough Advisors, LLC
new
-
8,480
8,480
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
12.51
799,139
1,473,320
0.01%

1–10 of 37

Are Funds Buying or Selling CERE?

Are funds buying CERE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CERE
No. of Funds

Unveiling Cerevel Therapeutics Holdings, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 10, 2024
fmr llc
-
0
SC 13G/A
Dec 08, 2023
bc perception holdings, lp
36.4%
65,679,781
SC 13D/A
Oct 18, 2023
bc perception holdings, lp
36.5%
65,679,781
SC 13D/A
Oct 18, 2023
pfizer inc
15.4%
27,349,211
SC 13D/A
Oct 17, 2023
perceptive advisors llc
6.2%
10,965,193
SC 13D/A
Apr 25, 2023
perceptive advisors llc
6.3%
9,918,068
SC 13D/A
Apr 21, 2023
perceptive advisors llc
6.4%
10,088,385
SC 13D
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Aug 18, 2022
bc perception holdings, lp
38.9%
60,632,356
SC 13D/A
Apr 07, 2022
pfizer inc
18.5%
27,349,211
SC 13D/A

Recent SEC filings of Cerevel Therapeutics Holdings, Inc.

View All Filings
Date Filed Form Type Document
Apr 03, 2024
4
Insider Trading
Apr 01, 2024
144
Notice of Insider Sale Intent
Mar 06, 2024
4
Insider Trading
Mar 04, 2024
144
Notice of Insider Sale Intent
Mar 04, 2024
4
Insider Trading
Feb 29, 2024
144
Notice of Insider Sale Intent
Feb 27, 2024
10-K
Annual Report
Feb 21, 2024
4
Insider Trading
Feb 16, 2024
8-K
Current Report
Feb 13, 2024
5
Insider Trading

Peers (Alternatives to Cerevel Therapeutics Holdings, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.9B
6.8B
-4.35% -31.01%
-8.68
5.98
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
2.23% -24.84%
-43.61
10.5
76.23% 61.08%
17.0B
2.4B
4.87% -7.82%
101.5
7.03
15.42% 18.43%
12.4B
3.7B
-9.49% -25.82%
20.67
3.34
8.87% 75.42%
MID-CAP
6.9B
396.6M
-6.36% -28.65%
-12.96
17.28
425.83% 18.94%
4.8B
-
-5.56% 77.93%
-7.36
60.35
54.84% -34.79%
3.4B
270.6M
0.03% 16.25%
-14.05
12.42
440.80% -27.84%
3.1B
240.7M
-13.61% -3.16%
-10.6
13.07
-1.03% -92.09%
2.9B
726.4M
-26.61% -2.10%
-47.61
4.02
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-1.37% -9.52%
26.21
4.7
85.90% -14.05%
596.2M
983.7M
-16.96% -52.88%
-1.09
0.61
-50.36% 17.16%
400.4M
881.7K
-0.31% 365.37%
-8.98
466.16
-77.61% -5.33%
268.8M
4.9M
-4.49% 31.28%
-1.99
55.23
-54.97% 51.72%
7.0M
2.1M
71.19% 77.19%
-0.26
2.14
-13.45% 66.37%

Cerevel Therapeutics Holdings, Inc. News

Latest updates
Defense World32 minutes ago

Cerevel Therapeutics Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2022Q32021Q32021Q22021Q12020Q42020Q32020Q22020Q22020Q12019Q4
Revenue49.7%3,9922,6661,34115.0014.002,5024,9904,990--
Operating Expenses74.3%95,06554,52750,51050,57141,89634,36235,156-37,702-
  S&GA Expenses64.8%23,68014,36813,21614,01022,44710,33612,97357.0010,743-
  R&D Expenses77.8%71,38540,15937,29436,56130,13524,02622,183-26,959-
Interest Expenses9792.3%1,28613.00--------
Income Taxes------3.00-5.00-16.00---
Earnings Before Taxes-61.0%-99,938-62,059-53,239-50,981-33,214-39,045-26,733--53,208-
EBT Margin-59.3%-1.42-890.44*-787.70*-669.37*------
Net Income-61.0%-99,938-62,059-53,239-50,981-86,327-39,040-26,717-57.11-53,208-
Net Income Margin-25.8%-1.42-1.13-1.02-906.54*------
Free Cashflow-79.2%-80,576-44,964-49,191-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q22019Q4
Assets51.3%1,2438228949301,0181,094597619689733391408445151151151121
  Current Assets46.4%1,0076887528419069995405545786753323503911.002.002.0087.00
    Cash Equivalents167.4%41615617615413724913892.0019767032734338813.0018.001.0084.00
  Net PPE-3.6%26.0027.0027.0027.0027.0028.0029.0030.0028.0028.0028.0028.0024.00---1.00
Liabilities3.7%57054954449949749014497.0011010497.0068.0061.008.006.006.0043.00
  Current Liabilities16.9%92.0079.0066.0063.0073.0060.0057.0035.0043.0031.0029.0034.0030.003.000.000.0015.00
  Long Term Debt0.1%337337336336335335-----------
    LT Debt, Non Current0.1%337337336336335335-----------
Shareholder's Equity146.8%6742733514325216034535215796292943403855.004.005.0078.00
  Retained Earnings-10.5%-1,400-1,267-1,171-1,072-967-874-775-684-616-557-495-441-390-3.12-0.23-0.06-244
  Additional Paid-In Capital34.7%2,0731,5391,5211,5001,4861,4731,2201,2071,1961,1877897827758.005.005.00322
Accumulated Depreciation12.6%13.0011.0010.009.007.006.005.004.003.002.001.000.000.00---0.00
Shares Outstanding15.1%181158157157157152148148137133127------
Float---2,200---1,576---995---173,420--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q22020Q12019Q4
Cashflow From Operations-34.1%-97,420-72,631-77,327-94,923-87,478-80,405-57,656-67,648-52,744-43,776-45,608-36,418-79,121-20,082-446-424-29,454-
  Share Based Compensation47.6%25,22217,08814,50812,59210,3789,69610,1488,5586,4866,1345,1846,1376573,4713,423-2,970-
Cashflow From Investing-392.3%-150,20851,39461,753110,783-26,732-387,85464,294-38,542-426,230-1,188-3,583-4,660136,279--149,500-149,500-2,556-
Cashflow From Financing42441.6%508,3721,19537,6141,4352,131578,64139,8162,6032,316387,58032,964742279,316-262151,209151,325--

CERE Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:   
Research and development$ 334,641$ 280,259$ 161,855
General and administrative112,62487,58958,243
Total operating expenses447,265367,848220,098
Loss from operations(447,265)(367,848)(220,098)
Interest income, net43,86513,537157
Interest expense(10,567)(3,918) 
Other income (expense), net (including related party amounts), (Notes 8, 11 and 20)(18,372)6,878(5,393)
Loss before income taxes(432,339)(351,351)(225,334)
Income tax benefit (provision), net(503)(160) 
Net loss$ (432,842)$ (351,511)$ (225,334)
Net loss per share, basic$ (2.67)$ (2.32)$ (1.65)
Net loss per share, diluted$ (2.67)$ (2.32)$ (1.65)
Weighted-average shares used in calculating net loss per share, basic162,056,405151,265,635136,576,536
Weighted-average shares used in calculating net loss per share, diluted162,056,405151,265,635136,576,536
Comprehensive loss:   
Net loss$ (432,842)$ (351,511)$ (225,334)
Other comprehensive income (loss):   
Changes in fair value attributable to instrument-specific credit risk (including related party amounts), (Notes 8, 10 and 20)(5,220)6,816(788)
Unrealized gains (losses) on securities available-for-sale3,894(2,733)(198)
Total other comprehensive income (loss)(1,326)4,083(986)
Comprehensive loss$ (434,168)$ (347,428)$ (226,320)

CERE Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEET - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 416,465$ 136,521
Marketable securities574,500755,509
Prepaid expenses and other current assets15,97313,621
Total current assets1,006,938905,651
Marketable securities185,19958,126
Property and equipment, net25,64727,467
Operating lease assets20,12521,820
Restricted cash1,9601,867
Other long-term assets3,4292,891
Total assets1,243,2981,017,822
Current liabilities:  
Accounts payable11,86310,061
Accrued expenses and other current liabilities76,91259,604
Operating lease liabilities, current portion3,4042,899
Total current liabilities92,17972,564
Operating lease liabilities, net of current portion27,78631,190
Financing liability, related party (Notes 8, 10 and 20)56,08228,674
Financing liability (Notes 8 and 10)56,08228,674
2027 convertible senior notes, net (Note 9)337,424335,482
Total liabilities569,553496,584
Commitments and contingencies (Notes 12, 17 and 18)
Stockholders’ equity:  
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value: 500,000,000 shares authorized; 181,362,064 and 156,502,285 shares issued and outstanding as of December 31, 2023 and 2022, respectively1816
Additional paid-in capital2,072,5531,485,880
Accumulated other comprehensive income (loss)1,7713,097
Accumulated deficit(1,400,597)(967,755)
Total stockholders’ equity673,745521,238
Total liabilities and stockholders’ equity$ 1,243,298$ 1,017,822
CERE
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEcerevel.com
 INDUSTRYBiotechnology
 EMPLOYEES322

Cerevel Therapeutics Holdings, Inc. Frequently Asked Questions


What is the ticker symbol for Cerevel Therapeutics Holdings, Inc.? What does CERE stand for in stocks?

CERE is the stock ticker symbol of Cerevel Therapeutics Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cerevel Therapeutics Holdings, Inc. (CERE)?

As of Wed Apr 10 2024, market cap of Cerevel Therapeutics Holdings, Inc. is 7.65 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CERE stock?

You can check CERE's fair value in chart for subscribers.

What is the fair value of CERE stock?

You can check CERE's fair value in chart for subscribers. The fair value of Cerevel Therapeutics Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cerevel Therapeutics Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CERE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cerevel Therapeutics Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether CERE is over valued or under valued. Whether Cerevel Therapeutics Holdings, Inc. is cheap or expensive depends on the assumptions which impact Cerevel Therapeutics Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CERE.

What is Cerevel Therapeutics Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 10 2024, CERE's PE ratio (Price to Earnings) is -17.67 and Price to Sales (PS) ratio is 33.1 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CERE PE ratio will change depending on the future growth rate expectations of investors.